Abstract：
BACKGROUND: Intratympanic steroids (ITS) in treating sudden sensorineural hearing loss (SSNHL) have become more widespread.
OBJECTIVE: This study investigates whether ITS treatment provides additional benefits when combined with systemic steroids (SS) in patients with severe and profound SSNHL.
METHODS: Patients diagnosed with severe and profound SSNHL were divided into two groups: SS group and SS combined with ITS group. Pure-tone audiometry was performed before and three months after treatment completion. The pure-tone average (PTA), frequency-specific hearing gains, and average values were compared between the groups.
RESULTS: The study included 57 patients (27 SS, 30 ITS), with a mean age of 50.09 ± 15.56. Before treatment: SS PTA 84.40 ± 15 dB HL, ITS 87.50 ± 9.38 dB HL (p = 0.36). After treatment: SS 62.2 ± 23.13 dB HL, ITS 65.17 ± 12.19 dB HL (p = 0.55). Average hearing gain: SS 22.19 ± 13.81 dB HL, ITS 22.33 ± 12.24 dB HL (p = 0.96). Frequency-specific gains were similar (p > 0.05). SS group: 12 slight improvement, 10 no improvement, 3 partial, 2 complete recovery. ITS group: 23 slight improvement, 6 no improvement, 1 partial.
CONCLUSIONS: In our study, combining ITS with SS treatment did not provide additional benefits in treating severe and profound SSNHL.
OBJECTIVE: This study investigates whether ITS treatment provides additional benefits when combined with systemic steroids (SS) in patients with severe and profound SSNHL.
METHODS: Patients diagnosed with severe and profound SSNHL were divided into two groups: SS group and SS combined with ITS group. Pure-tone audiometry was performed before and three months after treatment completion. The pure-tone average (PTA), frequency-specific hearing gains, and average values were compared between the groups.
RESULTS: The study included 57 patients (27 SS, 30 ITS), with a mean age of 50.09 ± 15.56. Before treatment: SS PTA 84.40 ± 15 dB HL, ITS 87.50 ± 9.38 dB HL (p = 0.36). After treatment: SS 62.2 ± 23.13 dB HL, ITS 65.17 ± 12.19 dB HL (p = 0.55). Average hearing gain: SS 22.19 ± 13.81 dB HL, ITS 22.33 ± 12.24 dB HL (p = 0.96). Frequency-specific gains were similar (p > 0.05). SS group: 12 slight improvement, 10 no improvement, 3 partial, 2 complete recovery. ITS group: 23 slight improvement, 6 no improvement, 1 partial.
CONCLUSIONS: In our study, combining ITS with SS treatment did not provide additional benefits in treating severe and profound SSNHL.
摘要：
背景：鼓室内类固醇（ITS）治疗突发性感觉神经性听力损失（SSNHL）已变得越来越普遍。
目的：本研究调查了ITS治疗与全身性类固醇（SS）联合治疗严重和严重SSNHL患者是否具有额外的益处。
方法：将诊断为严重和深度SSNHL的患者分为两组：SS组和SS联合ITS组。在治疗完成前和治疗后三个月进行纯音测听。纯音平均(PTA)，特定频率的听力增益，并比较各组间的平均值。
结果：该研究包括57例患者（27例SS，30ITS)，平均年龄50.09±15.56。治疗前：SSPTA84.40±15dBHL，ITS87.50±9.38dBHL(p=0.36)。治疗后：SS62.2±23.13dBHL，ITS65.17±12.19dBHL(p=0.55)。平均听力增益：SS22.19±13.81dBHL，ITS22.33±12.24dBHL(p=0.96)。频率特异性增益相似(p>0.05)。SS组：12略有改善，10没有改进，3部分，2完全恢复。ITS组：23略有改善，6没有改进，1部分。
结论：在我们的研究中，将ITS与SS治疗相结合,在治疗严重和深度SSNHL方面没有额外的益处.
目的：本研究调查了ITS治疗与全身性类固醇（SS）联合治疗严重和严重SSNHL患者是否具有额外的益处。
方法：将诊断为严重和深度SSNHL的患者分为两组：SS组和SS联合ITS组。在治疗完成前和治疗后三个月进行纯音测听。纯音平均(PTA)，特定频率的听力增益，并比较各组间的平均值。
结果：该研究包括57例患者（27例SS，30ITS)，平均年龄50.09±15.56。治疗前：SSPTA84.40±15dBHL，ITS87.50±9.38dBHL(p=0.36)。治疗后：SS62.2±23.13dBHL，ITS65.17±12.19dBHL(p=0.55)。平均听力增益：SS22.19±13.81dBHL，ITS22.33±12.24dBHL(p=0.96)。频率特异性增益相似(p>0.05)。SS组：12略有改善，10没有改进，3部分，2完全恢复。ITS组：23略有改善，6没有改进，1部分。
结论：在我们的研究中，将ITS与SS治疗相结合,在治疗严重和深度SSNHL方面没有额外的益处.
